Serendia v. Cutera: Voluntary Dismissal in Dermatological Device Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Serendia, LLC v. Cutera, Inc. |
| Case Number | 1:23-cv-00222 (D. Del.) |
| Court | District of Delaware |
| Duration | March 1, 2023 – April 3, 2024 399 days |
| Outcome | Voluntary Dismissal |
| Patents at Issue | |
| Accused Products | Cutera’s electrically based medical treatment devices (dermatological treatment systems and skin treatment apparatus) |
Case Overview
In a case that underscores the strategic complexity of medical device patent litigation, Serendia, LLC voluntarily dismissed its patent infringement action against Cutera, Inc. before the defendant ever filed an answer. Filed on March 1, 2023, in the District of Delaware and closed on April 3, 2024, Case No. 1:23-cv-00222 involved six patents spanning electrically based dermatological treatment devices and skin treatment methods — a technology area experiencing intense IP competition.
The dismissal, filed under Federal Rule of Civil Procedure 41(a)(1)(A)(i), raises important questions about plaintiff strategy, pre-answer settlement dynamics, and the economics of patent assertion in the medical aesthetics sector.
The Parties
⚖️ Plaintiff
A patent holding entity asserting rights over a portfolio of medical treatment and dermatological device patents, consistent with patent assertion entities (PAEs).
🛡️ Defendant
A publicly traded medical device company headquartered in Brisbane, California, specializing in aesthetic and dermatological energy-based treatment systems.
Patents at Issue
Serendia asserted six U.S. patents, all directed to dermatological and medical treatment technologies. The portfolio spans a generation of patent filings, reflecting a layered IP strategy across continuation and related applications in the electrical medical device space.
- • US11406444B2 — Electrically based medical treatment device and method
- • US9775774B2 — Method, system, and apparatus for dermatological treatment
- • US10058379B2 — Method, system, and apparatus for dermatological treatment
- • US9320536B2 — Skin treatment apparatus and method
- • US9480836B2 — Skin treatment apparatus and method
- • US10869812B2 — Electrically based medical treatment device and method
Designing a similar dermatological device?
Check if your medical device design might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
Serendia, LLC voluntarily dismissed this action against Cutera, Inc. without prejudice, pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). Each party agreed to bear its own costs, expenses, and attorneys’ fees. No damages award, injunctive relief, or court-ordered finding on validity or infringement was issued.
Key Legal Issues
The critical legal mechanism here is the Rule 41(a)(1)(A)(i) voluntary dismissal, which permits a plaintiff to dismiss without prejudice before the defendant answers. The 399-day duration between filing and dismissal, despite no answer being filed, suggests the parties engaged in extended off-record negotiations during this period, likely leading to a confidential settlement or licensing agreement.
While this case produced no precedential ruling, its procedural posture carries instructive value for understanding pre-answer dismissals in patent assertion entity (PAE) litigation.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the medical aesthetics device market. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 6 asserted patents and their families
- See which companies are most active in dermatological device patents
- Understand patent assertion trends in medical aesthetics
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Electrically based dermatological treatment devices
6 Asserted Patents
In dermatological device technology
Design-Around Options
Can be explored for certain claims
✅ Key Takeaways
Rule 41(a)(1)(A)(i) pre-answer dismissals preserve plaintiff optionality; always assess prior dismissal history under the two-dismissal rule.
Search related case law →Multi-patent portfolios in continuation families create layered infringement exposure that complicates early case evaluation.
Explore precedents →Delaware remains the dominant venue for medical device patent assertions; local counsel selection is a material strategic variable.
View Delaware court statistics →Frequently Asked Questions
Six U.S. patents: US11406444B2, US9775774B2, US10058379B2, US9320536B2, US9480836B2, and US10869812B2 — all directed to dermatological and electrically based medical treatment devices and methods.
Serendia filed a Rule 41(a)(1)(A)(i) notice of voluntary dismissal before Cutera answered the complaint. No reason was stated publicly; the parties agreed each would bear its own costs, which is consistent with a negotiated resolution.
The asserted patents remain enforceable. Serendia retains the right to refile against Cutera or assert these patents against other defendants, making ongoing portfolio monitoring essential for competitors in this space.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:23-cv-00222 (District of Delaware)
- USPTO Patent Center — Asserted Patents (e.g., US11406444B2)
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41
- PatSnap — IP Solutions for Medical Device Industry
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.